Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made under the company’s 2025 A-Share Option Scheme, covers 100 eligible participants and represents about 0.0272% of Fosun Pharma’s total issued share capital.

Each option carries an exercise price of RMB 27.93 per A-share. Several grantees are classified as connected persons at the subsidiary level, rendering the allocation a connected transaction under Hong Kong Listing Rule 14A. Nevertheless, all applicable percentage ratios are below 1%, so the transaction qualifies for exemptions from shareholders’ approval, annual review, and further disclosure requirements.

The decision was approved by the board on the same day as the announcement, with Chairman Chen Yuqing signing on behalf of the board. No additional financial terms or performance conditions were detailed in the filing.